Home › Diffuse Large B-Cell Lymphoma › Pennsylvania › Pittsburgh
Diffuse Large B-Cell Lymphoma clinical trials in Pittsburgh, PA
6 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
RecruitingPhase 2
- West Penn Hospital, Pittsburgh
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
RecruitingPhase 1/2
- West Penn Hospital, Pittsburgh
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RecruitingPhase 3
- Allegheny Health Network, Pittsburgh
DALY II USA/ MB-CART2019.1 for DLBCL
RecruitingPhase 2
- Allegheny Health Network Cancer Institute, Pittsburgh
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
RecruitingPhase 2
- AHN Cancer Institute - West Penn Hospital, Pittsburgh
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
RecruitingPhase 2
- Allegheny Health Network (AHN) West Penn Hospital, Pittsburgh
Diffuse Large B-Cell Lymphoma trials in other cities
- New York City, NY21 studies
- Baldwin Park, CA19 studies
- Chicago, IL18 studies
- Houston, TX17 studies
- Los Angeles, CA17 studies
- Milwaukee, WI16 studies
- Boston, MA16 studies
- Philadelphia, PA15 studies
- Portland, OR15 studies
- Durham, NC14 studies
- Nashville, TN14 studies
- Dallas, TX13 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer38 studies
- Colorectal Cancer32 studies
- Metastatic Cancer31 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer24 studies
- Lung Cancer23 studies
- Prostate Cancer23 studies
- Depression22 studies
- Head and Neck Squamous Cell Carcinoma22 studies
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.